The researchers wrote that that a numerically larger proportion of patients with myasthenia gravis (MG) stopped or reduced their doses of immunosuppressive therapies than started or increased, and that symptom improvement or worsening were the main reasons for changes to concomitant therapy.
Eculizumab (Soliris), a particularly high-cost biologic that treats rare and ultra-rare diseases, has recently seen its first biosimilar launch in Russia. While US and European competition from biosimilars will likely take several years more, multiple biosimilar developers, including Amgen and Samsung Bioepis, are developing their own biosimilars referencing Soliris.
During the coming week’s 2019 annual meeting of the American Academy of Neurology, held May 4-10 in Philadelphia, Pennsylvania, researchers will report new data on eculizumab in one of the drug’s more recently approved indications: generalized myasthenia gravis (MG).
The research team will present an interim analysis of the changes in concomitant immunosuppressive therapy used by patients with generalized, refractory, and anti-acetylcholine receptor antibody—positive MG during a phase 3, open-label extension of a study of eculizumab. The data cut-off for this analysis was December 31, 2017.
The extension enrolled 117 patients who had completed the REGAIN study, a 6-month, randomized, double-blind, placebo-controlled study of the biologic therapy. While during the REGAIN study patients were not allowed to receive concomitant therapy, during the extension, participants could, at the investigator’s discretion, have their concomitant therapy added to their 1200 mg of eculizumab that was given every 2 weeks.
Median eculizumab treatment from the open-label extension baseline was 22.7 months (range, 1 day to 37.3 months). At baseline of the extension, 98.3% of the patients were receiving at least 1 immunosuppressive therapy.
During the extension, 67.5% stopped or reduced the dose of their immunosuppressive therapy on 439 occasions in total, mostly because their MG symptoms had improved (46.2% of patients on 256 occasions). On 63 occasions, 53.8% of the patients started or increased their dose of immunosuppressive agents; in 32.5% (and on 89 occasions), this start or increase was due to worsening of MG symptoms.
The authors concluded that a numerically larger proportion of patients stopped or reduced their doses of immunosuppressive therapies than started or increased, and that symptom improvement or worsening were the main reasons for changes to concomitant therapy.
Reference
Nowak RJ, Muppidi S, Beydoun SR, O’Brien F, Yountz M, Howard JF. Changes in concomitant immunosuppressive therapy use during a phase 3 open-label study of eculizumab in adults with generalized myasthenia gravis: an interim analysis. Presented at: 2019 American Academy of Neurology Annual Meeting; May 4-10, 2019; Philadelphia, PA. Abstract P5.2-080.
Biosimilar Substitution Can Reduce TCOC, Improve Provider Performance in Value-Based Payment Models
December 7th 2023A simulation study estimated the impact of biosimilar substitution on total cost of care (TCOC) and provider financial performance in the final performance period of the Oncology Care Model.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
IQVIA Highlights Opportunity to Cash In on Biosimilars for Biologics Losing Market Exclusivity
November 29th 2023A report from IQVIA noted that Europe could miss out on €15 billion in cost savings by not having biosimilars for medications about to lose market exclusivity, shedding light on the implications for overall health care savings and ultimately, patient access.
Pipelines and Preparation: How the US Can Prepare for More RA Biosimilars
April 16th 2023What can practices do to prepare for all the biosimilars to treat rheumatoid arthritis (RA) coming down the pipeline? And how can they ensure that the lower-than-anticipated adoption rates for infliximab biosimilars are not repeated? Robert Zutaut, RPh, from McKesson Provider Solutions, tackles all this and more on this episode of Not So Different.
Study: Biosimilar Use, Dose Rounding Produce More Cost Savings Than Either Strategy Alone
November 18th 2023A retrospective study of New England patients receiving trastuzumab or bevacizumab found that combining dose rounding and biosimilar use resulted in greater cost savings than either strategy alone.